EP Patent

EP3691652A1 — Methods of treating bacterial infections

Assigned to Melinta Subsidiary Corp · Expires 2020-08-12 · 6y expired

What this patent protects

The present invention provides methods of treating a bacterial infection in immunocompromised subjects and subjects having one or more underlying malignancies that include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated may…

USPTO Abstract

The present invention provides methods of treating a bacterial infection in immunocompromised subjects and subjects having one or more underlying malignancies that include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated may include a subject having a history of leukemia or lymphoma in progress, a subject having had an organ transplant, a stem cell transplant, a bone marrow transplant, or a splenectomy, a subject receiving immunosuppressive drugs, a subject receiving ablative bone marrow chemotherapy, a subject having neutropenia, and a subject suffering from or having suffered from malignancy.

Drugs covered by this patent

Patent Metadata

Patent number
EP3691652A1
Jurisdiction
EP
Classification
—
Expires
2020-08-12
Drug substance claim
No
Drug product claim
No
Assignee
Melinta Subsidiary Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.